{"description":"Documents matching 'tesamorelin'","count":5,"total_pages":1,"results":[{"title":"HISA Anti-Doping and Medication Control Rule","type":"Notice","abstract":"The Horseracing Integrity and Safety Act of 2020 recognizes a self-regulatory nonprofit organization, the Horseracing Integrity and Safety Authority, which is charged with developing proposed rules on a variety of subjects. Those proposed rules and later proposed rule modifications take effect only if approved by the Federal Trade Commission. The proposed rules and rule modifications must be published in the Federal Register for public comment. Thereafter, the Commission has 60 days from the date of publication to approve or disapprove the proposed rule or rule modification. The Authority submitted to the Commission a proposed rule on Anti-Doping and Medication Control on December 30, 2022. The Office of the Secretary of the Commission determined that the proposal complied with the Commission's rule governing such submissions. This document publicizes the Authority's proposed rule's text and explanation, and it seeks public comment on whether the Commission should approve or disapprove the proposed rule. This document is substantially similar to the document published on October 28, 2022, as corrected on November 4, 2022, and the Commission will consider all comments filed in response to that document as well as all comments filed in response to this document.","document_number":"2023-00957","html_url":"https://www.federalregister.gov/documents/2023/01/26/2023-00957/hisa-anti-doping-and-medication-control-rule","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2023-01-26/pdf/2023-00957.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2023-00957.pdf?1674654316","publication_date":"2023-01-26","agencies":[{"raw_name":"FEDERAL TRADE COMMISSION","name":"Federal Trade Commission","id":192,"url":"https://www.federalregister.gov/agencies/federal-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/192","parent_id":null,"slug":"federal-trade-commission"}],"excerpts":"\n \n CONTROLLED \n S7 \n B \n Tepoxalin \n NSAID \n Zubrin \n \n \n BANNED \n S0 \n \n Terazosin \n Antihypertensive \n Generic \n \n \n BANNED \n S3 \n \n Terbutaline \n Bronchodilator \n Brethine \n \n \n BANNED \n S0 \n \n Terfenadine \n Antihistamine \n Lacks FDA approval \n \n \n BANNED \n S2 \n \n <span class=\"match\">Tesamorelin</span> \n Growth Hormone \n Egrifta \n \n \n BANNED \n S4 \n \n Testolactone \n Aromatase inhibitor \n Teslac. DEA Schedule III \n \n \n BANNED \n S2 \n \n Testolone \n Selective Androgen Receptor Modulator (SARM) \n Lacks FDA approval \n \n \n BANNED—Fillies and Mares (unless in foal) \n S1 \n \n Testosterone"},{"title":"HISA Anti-Doping and Medication Control Rule","type":"Notice","abstract":"The Horseracing Integrity and Safety Act of 2020 recognizes a self-regulatory nonprofit organization, the Horseracing Integrity and Safety Authority, which is charged with developing proposed rules on a variety of subjects. Those proposed rules and later proposed rule modifications take effect only if approved by the Federal Trade Commission. The proposed rules and rule modifications must be published in the Federal Register for public comment. Thereafter, the Commission has 60 days from the date of publication to approve or disapprove the proposed rule or rule modification. The Authority submitted to the Commission a proposed rule on Anti-Doping and Medication Control on August 17, 2022 and supplemented on October 13, 2022. The Office of the Secretary of the Commission determined that the proposal complied with the Commission's rule governing such submissions. This document publicizes the Authority's proposed rule text and explanation, and it seeks public comment on whether the Commission should approve or disapprove the proposed rule.","document_number":"2022-22970","html_url":"https://www.federalregister.gov/documents/2022/10/28/2022-22970/hisa-anti-doping-and-medication-control-rule","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2022-10-28/pdf/2022-22970.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2022-22970.pdf?1666874715","publication_date":"2022-10-28","agencies":[{"raw_name":"FEDERAL TRADE COMMISSION","name":"Federal Trade Commission","id":192,"url":"https://www.federalregister.gov/agencies/federal-trade-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/192","parent_id":null,"slug":"federal-trade-commission"}],"excerpts":"\n \n CONTROLLED \n S7 \n B \n Tepoxalin \n NSAID \n Zubrin \n \n \n BANNED \n S0 \n \n Terazosin \n Antihypertensive \n Generic \n \n \n BANNED \n S3 \n \n Terbutaline \n Bronchodilator \n Brethine \n \n \n BANNED \n S0 \n \n Terfenadine \n Antihistamine \n Lacks FDA approval \n \n \n BANNED \n S2 \n \n <span class=\"match\">Tesamorelin</span> \n Growth Hormone \n Egrifta \n \n \n BANNED \n S4 \n \n Testolactone \n Aromatase inhibitor \n Teslac. DEA Schedule III \n \n \n BANNED \n S2 \n \n Testolone \n Selective Androgen Receptor Modulator (SARM) \n Lacks FDA approval \n \n \n BANNED—Fillies and Mares (unless in foal) \n S1 \n \n Testosterone"},{"title":"Determination of Regulatory Review Period for Purposes of Patent Extension; EGRIFTA","type":"Notice","abstract":"The Food and Drug Administration (FDA) has determined the regulatory review period for EGRIFTA and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Director of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.","document_number":"2012-10808","html_url":"https://www.federalregister.gov/documents/2012/05/04/2012-10808/determination-of-regulatory-review-period-for-purposes-of-patent-extension-egrifta","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2012-05-04/pdf/2012-10808.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2012-10808.pdf?1336049498","publication_date":"2012-05-04","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B). \n FDA recently approved for marketing the human drug product EGRIFTA (<span class=\"match\">tesamorelin</span> acetate). EGRIFTA is indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for EGRIFTA (U.S. Patent No. 5,861,379) from"},{"title":"Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting","type":"Notice","abstract":null,"document_number":"2010-6169","html_url":"https://www.federalregister.gov/documents/2010/03/22/2010-6169/endocrinologic-and-metabolic-drugs-advisory-committee-notice-of-meeting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-03-22/pdf/2010-6169.pdf","public_inspection_pdf_url":null,"publication_date":"2010-03-22","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.\n \n \n Agenda \n : On May 27, 2010, the committee will discuss the safety and efficacy of new drug application (NDA) 22-505, EGRIFTA (<span class=\"match\">tesamorelin</span> acetate), sterile lyophilized powder for injection, by Theratechnologies, Inc. EGRIFTA is an analogue (a chemical compound that resembles another compound in structure) of growth hormone releasing hormone (GHRH). The proposed indication (use) for EGRIFTA in this application"},{"title":"Endocrinologic and Metabolic Drugs Advisory Committee; Notice of Meeting","type":"Notice","abstract":null,"document_number":"2010-785","html_url":"https://www.federalregister.gov/documents/2010/01/19/2010-785/endocrinologic-and-metabolic-drugs-advisory-committee-notice-of-meeting","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2010-01-19/pdf/2010-785.pdf","public_inspection_pdf_url":null,"publication_date":"2010-01-19","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"Food and Drug Administration","name":"Food and Drug Administration","id":199,"url":"https://www.federalregister.gov/agencies/food-and-drug-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/199","parent_id":221,"slug":"food-and-drug-administration"}],"excerpts":"the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.\n \n \n Agenda: \n The committee will discuss the safety and efficacy of new drug application (NDA) 22-505, for EGRIFTA (<span class=\"match\">tesamorelin</span> acetate) sterile lyophilized powder for injection, by Theratechnologies, Inc. EGRIFTA is an analogue (a chemical compound that resembles another compound in structure) of growth hormone releasing hormone (GHRH). The proposed indication (use) for EGRIFTA in this application"}]}